NeoGenomics Laboratories, Inc. (NEO)Segall Bryant & Hamill, LLC reduced its stake -599K shares

1.13M

Shares reported · -599K vs prior quarter

0.12%

Disclosed portfolio weight

$8.41M

Reported value

Holdings as of

Mar 31, 2026

Filed

May 22, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Apr 24, 2026Federal contract · $644K obligatedDepartment of Veterans Affairs awarded NEOGENOMICS INC: $644K obligated to date
2. Apr 28, 2026Company filing · Form 8-K · ResultsReported its results
3. May 21, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On May 21, 2026, NeoGenomics, Inc. (the "Company") held an annual meeting (the "Annual Meeting") of its stockholders. At the Annual Meeting, stockholders approved an amendment (the "Amendment") to the Company's 2023 Equity Incentive Plan (the "Equity Incentive Plan") to increase the number of shares authorized for issuance thereunder by 5,000,000 shares.”
4. May 22, 2026Federal contract · $402K obligatedDepartment of Health and Human Services awarded NEOGENOMICS INC: $402K obligated to date

What came next

1. Jun 11, 2026Federal contract · $100K obligatedDepartment of Veterans Affairs awarded NEOGENOMICS INC: $100K obligated to date
2. Jun 16, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
3. Jun 17, 2026Federal contract · $494K obligatedDepartment of Veterans Affairs awarded NEOGENOMICS INC: $494K obligated to date
4. Jun 23, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On June 23, 2026, the Board of Directors (the "Board") of NeoGenomics, Inc. (the "Company") increased the size of the Board from nine to ten directors and appointed Carolyn S. Starrett as a director to fill the newly created vacancy, effective immediately.”
5. Jul 28, 2026Company filing · Form 8-K · ResultsReported its results
6. Aug 7, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On August 11, 2026, NeoGenomics, Inc. (the “Company”) announced that Alicia Olivo, EVP, General Counsel & Business Development, would transition from her role with the Company and cease to serve as General Counsel effective as of September 21, 2026.”
7. Aug 7, 2026CongressDisclosed purchase of NEO — reported range $1,001 - $15,000

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for NeoGenomics Laboratories, Inc.

For NeoGenomics Laboratories, Inc., OQRO holds 1 Congress trade report and 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its NEO page.

How this filing works

• SEC Form 13F

Other disclosures at NeoGenomics Laboratories, Inc.

• House Clerk periodic transaction reportSep 10, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• USAspending.gov award recordJun 17, 2026
• USAspending.gov award recordJun 11, 2026
• USAspending.gov award recordMay 22, 2026

Everything OQRO holds on this company is on its NEO page.